[Retigabine - a new antiepileptic drug with a different mechanism of action].
Ewa Zwierzyńska, Bogusława Pietrzak
Index: Postepy. Hig. Med. Dosw. 67 , 973-81, (2013)
Full Text: HTML
Abstract
Retigabine belongs to a new generation of antiepileptic drugs. Its mechanism of action is different from that previously known. Retigabine opens potassium channels of subfamily Kv 7, especially Kv 7.2 and Kv 7.3. The drug enhances GABA-ergic transmission. It is well absorbed from the digestive system and undergoes metabolism via glucuronidation and acetylation. There is no interaction between retigabine and other antiepileptic drugs except lamotrigine. The drug has been registered as treatment of partial onset seizures with or without secondary generalization in adults. The efficacy of retigabine is being tested in other types of seizures and disorders characterized by neuronal hyperexcitability. Neuroprotective activity of retigabine is also being researched.
Related Compounds
Related Articles:
2014-04-01
[Epilepsia 55(4) , 601-8, (2014)]
2013-11-01
[Expert Opin. Drug Saf. 12(6) , 847-55, (2013)]
Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
2012-09-01
[Clin. Ther. 34(9) , 1845-56.e1, (2012)]
2015-01-01
[Mol. Pharmacol. 87(1) , 31-8, (2015)]
[Retigabine. A novel anticonvulsant drug for the adjunctive treatment of partial seizures].
2012-05-01
[Med. Monatsschr. Pharm. 35(5) , 166-71, (2012)]